Comprehensive Guide to Sedative-Hypnotic Drugs in Psychiatry

Introduction to Sedative Agents and Clinical Definitions

• Definition of Sedatives: Sedatives are central nervous system (CNS) depressants that reduce neuronal excitability, producing a spectrum of effects ranging from mild anxiolysis and sedation to deep anesthesia.
• Alternative Nomenclature: They are frequently referred to as sedative-hypnotics or CNS depressants.
• Primary Mechanisms: Most classes act primarily on $GABA_{A}$ receptors, although other molecular targets may be involved depending on the drug class.
• Clinical Utility: Clinically used for the management of anxiety, insomnia, seizures, procedural sedation, and anesthesia.
• Sedative vs. Hypnotic Terminology:
  • Sedative: Characterized by a calming effect.
  • Hypnotic: Characterized by the induction of sleep.
  • Dose-Dependency: A single drug can function as a sedative at a low dose and as a hypnotic at a higher dose.

Historical Evolution of Sedatives

• $1860s$: Introduction of Chloral hydrate, the first synthetic hypnotic agent.
• $1903$: Synthesis of the first barbiturate (barbital) by Emil Fischer.
• $1912$: Phenobarbital is introduced for the treatment of epilepsy and for sedation.
• $1950s$: Meprobamate (Miltown) becomes the first widely used anxiolytic.
• $1960$: Chlordiazepoxide (Librium), the first benzodiazepine, is discovered by Leo Sternbach.
• $1963$: Diazepam (Valium) is launched; it eventually became the best-selling drug in the world.
• $1990s$: Introduction of Z-drugs (zolpidem, zaleplon) for safer management of insomnia.
• $2005$: Ramelteon is approved by the FDA as the first melatonin agonist for insomnia.
• $2014$: Suvorexant is approved as the first orexin antagonist.

Classification and Pharmacological Categories

• Benzodiazepines: Includes Diazepam, lorazepam, clonazepam, alprazolam, and midazolam.
• Barbiturates: Includes Phenobarbital, thiopental, pentobarbital, and secobarbital.
• Z-Drugs (Non-BZD Hypnotics): Includes Zolpidem, zaleplon, and eszopiclone.
• Antihistamines: Includes Diphenhydramine, hydroxyzine, and promethazine.
• Antipsychotics: Includes Quetiapine, olanzapine, and chlorpromazine (where sedation is either a primary or side effect).
• Melatonin Agonists: Includes Ramelteon and melatonin (used for sleep onset with minimal abuse potential).
• Orexin Antagonists: Includes Suvorexant and lemborexant (used for sleep maintenance).
• Anesthetic Agents: Includes Propofol, ketamine, and dexmedetomidine (typically for ICU or procedural use).

Benzodiazepines: Overview, Structure, and Potency

• Discovery: Discovered in $1955$ by Leo Sternbach at Hoffmann-La Roche.
• Safety Profile: Originally developed as a safer alternative to barbiturates due to a wide therapeutic index.
• Chemical Structure: All share a common benzene ring fused to a diazepine ring structure.
• Classification by Duration of Action:
  • Ultra-short: Triazolam ($t\frac{1}{2} \approx 2-5\,h$).
  • Short: Lorazepam, alprazolam ($t\frac{1}{2} \approx 6-20\,h$).
  • Intermediate: Temazepam ($t\frac{1}{2} \approx 8-25\,h$).
  • Long-acting: Diazepam, chlordiazepoxide ($t\frac{1}{2} \approx 20-100\,h$).
• Classification by Potency: High potency agents include clonazepam and alprazolam.
• Prototype Drug: Diazepam (Valium) remains the reference compound for the class.
• Common Benzodiazepines and Specific Indications:
  • Diazepam: Anxiety, seizures, muscle spasms.
  • Lorazepam: Status epilepticus, acute anxiety.
  • Clonazepam: Panic disorder, seizures.
  • Alprazolam: Panic disorder, Generalized Anxiety Disorder (GAD).
  • Midazolam: Procedural sedation and ICU use.
  • Temazepam: Insomnia.
  • Chlordiazepoxide: Alcohol withdrawal.
  • Nitrazepam: Insomnia, myoclonic epilepsy.

Mechanism of Action (MOA) of Benzodiazepines

• Receptor Binding: Benzodiazepines (BZDs) bind to the $\gamma$-aminobutyric acid type A ($GABA_{A}$) receptor.
• Binding Site: Located at the interface of the $\alpha$ and $\gamma$ subunits.
• Pharmacological Action: BZDs are Positive Allosteric Modulators (PAMs). They are NOT agonists; they require the presence of GABA to function.
• Ion Channel Dynamics: BZDs increase the frequency of Chlorine ($Cl^{-}$) channel opening (in contrast to barbiturates which increase duration).
• Cellular Effect: Enhanced $Cl^{-}$ influx leads to hyperpolarization, which reduces neuronal firing.
• Safety Advantage: Because they require GABA to be present, they cannot open the channel alone, contributing to a safer profile than barbiturates.
• Clinical Effects Linked to Subunits:
  • Anxiolytic effects: Mediated by $\alpha2/\alpha3$ subunits.
  • Sedation/Hypnotic effects: Mediated by $\alpha1$ subunits.
  • Anticonvulsant effects: Mediated by $\alpha1/\alpha2/\alpha5$ subunits.
  • Muscle relaxant effects: Mediated by $\alpha2/\alpha3$ subunits in the spinal cord.
  • Amnesia: Mediated by $\alpha1$ subunits in the hippocampus.

Barbiturates: Classical Sedatives and Their Pharmacology

• Origin: Derived from barbituric acid (malonylurea).
• Mechanism of Action:
  • Bind to the $GABA_{A}$ receptor to increase the duration of $Cl^{-}$ channel opening.
  • At high doses, they can directly open the $Cl^{-}$ channel independent of GABA presence.
  • They also inhibit AMPA/kainate (glutamate) receptors.
• Spectrum of Depression: Dose-dependent CNS depression follows a trajectory of: sedation $\rightarrow$ hypnosis $\rightarrow$ anesthesia $\rightarrow$ coma $\rightarrow$ death.
• Safety Concerns: Narrow therapeutic index; lethal dose is close to the therapeutic dose. They are strong inducers of $CYP450$ enzymes, leading to significant drug interactions.
• Specific Barbiturate Agents and Uses:
  • Phenobarbital: Long-acting; used for epilepsy and neonatal seizures.
  • Thiopental: Ultra-short-acting; used for IV anesthesia induction.
  • Pentobarbital: Short-acting; used for procedural sedation.
  • Secobarbital: Short-acting; limited use for insomnia.
  • Primidone: Intermediate-acting; an anticonvulsant converted to phenobarbital in the body.

Non-Benzodiazepine Hypnotics (Z-Drugs)

• Mechanism: Positive allosteric modulators of the $GABA_{A}$ receptor, similar to BZDs.
• Selectivity: Preferentially bind to the $\alpha1$ subunit, leading to sedation with fewer anxiolytic or muscle-relaxant effects.
• Key Agents:
  • Zolpidem (Ambien): Most prescribed hypnotic worldwide. $t\frac{1}{2} \approx 2\,h$. Indicated for sleep-onset insomnia.
  • Zaleplon (Sonata): Very short $t\frac{1}{2} \approx 1\,h$. Useful for middle-of-the-night awakening; minimal residual next-day sedation.
  • Eszopiclone (Lunesta): Longer $t\frac{1}{2} \approx 6\,h$. Approved for both sleep onset and sleep maintenance. Often causes a metallic taste.
  • Zopiclone: A racemic mixture (eszopiclone is the active S-enantiomer). $t\frac{1}{2} \approx 5\,h$. Used commonly in Europe and Asia.
• Safety and Regulations: FDA has issued a Black Box Warning for complex sleep behaviors (e.g., sleep-walking, sleep-driving). Contraindicated in sleep apnea and respiratory insufficiency.

Antihistamines as Sedative Agents

• Mechanism: First-generation $H_{1}$ antihistamines cross the Blood-Brain Barrier (BBB). Sedation is achieved via $H_{1}$ receptor antagonism and muscarinic antagonism in the brain.
• Availability: Over-the-counter (OTC) status for many.
• Tolerance: Develops rapidly, often within days of use. Not recommended for long-term insomnia management.
• Drug Profiles:
  • Diphenhydramine (Benadryl): Most common OTC sleep aid. $t\frac{1}{2} \approx 9\,h$. Significant anticholinergic effects; risk of delirium in the elderly.
  • Hydroxyzine (Atarax/Vistaril): Used for anxiety and sedation. Non-addictive and possesses antiemetic properties.
  • Promethazine: A phenothiazine-derived agent. Used for procedural sedation, nausea/vomiting in pregnancy (NVP), and motion sickness.
• Anticholinergic Side Effects: Dry mouth, blurred vision, urinary retention, constipation, tachycardia, confusion, and delirium.

Antipsychotics with Sedative Properties

• Sedative Mechanisms: Interaction with $H_{1}$ receptors, $\alpha1$-adrenergic blockade, and $D_{2}$ antagonism.
• Indications: Acute agitation, insomnia secondary to psychiatric disorders, or as adjunct sedation.
• Key Drugs:
  • Quetiapine: Strong $H_{1}$ block. Widely used off-label for sleep at low doses ($25-100\,mg$).
  • Olanzapine: IM formulation used for acute agitation.
  • Chlorpromazine: First-generation agent; provides powerful sedation.
  • Haloperidol: Less inherently sedating but utilized for delirium in the ICU.
  • Clozapine: Highly sedating; reserved for refractory schizophrenia.
• Risks: Metabolic syndrome (weight gain, hyperglycemia), Extrapyramidal symptoms (EPS), Tardive dyskinesia, Orthostatic hypotension, and QTc prolongation.

Melatonin Receptor Agonists and Orexin Receptor Antagonists

Melatonin Receptor Agonists

• Action: Targets $MT_{1}$ and $MT_{2}$ receptors in the Suprachiasmatic Nucleus (SCN).
• Clinical Benefit: Promotes sleep onset by reducing sleep-onset latency; mimics physiological sleep without next-day impairment.
• Dependencies: No risk of dependence or abuse. Schedule-free.
• Agents:
  • Ramelteon (Rozerem): Only FDA-approved melatonin agonist; $t\frac{1}{2} \approx 1-2\,h$ with an active metabolite called M-II.
  • Tasimelteon: Specifically for non-$24$-hour sleep-wake disorder.
  • OTC Melatonin: Used for circadian rhythm adjustment and jet lag.

Orexin Receptor Antagonists (DORAs)

• Action: Dual Orexin Receptor Antagonists block $OX_{1}R$ and $OX_{2}R$. Orexin (hypocretin) normally promotes wakefulness.
• Novel MOA: Induces sleep by reducing wakefulness signals rather than forcing global sedation.
• Agents:
  • Suvorexant (Belsomra): FDA-approved $2014$ for onset and maintenance.
  • Lemborexant (Dayvigo): FDA-approved $2019$ for insomnia.
  • Daridorexant (Quviviq): FDA-approved $2022$; improves daytime function.
• Side Effects: Somnolence, sleep paralysis, and hypnagogic hallucinations.

Comprehensive Pharmacokinetics of Sedatives

Pharmacokinetic Data Table

Key PK Principles

• Absorption: Well absorbed orally (bioavailability $70-90\%$). Lipophilic drugs (like diazepam) are absorbed faster. IV route is used for emergencies to bypass first-pass metabolism.
• Distribution: Highly lipophilic drugs cross the BBB readily. BZDs are highly protein-bound ($85-99\%$ to albumin). They have a large Volume of Distribution ($V_d$) and redistribute from the brain to adipose tissue.
• Metabolism: Primary hepatic metabolism via $CYP450$ (mainly $CYP3A4, CYP2C19$). Diazepam produces long-acting active metabolites. The "LOT" Rule: Lorazepam, Oxazepam, and Temazepam undergo direct glucuronidation and are safer for patients with hepatic impairment.
• Elimination: Renal excretion of conjugated metabolites. Elderly patients exhibit reduced clearance, leading to toxicity risk.

Clinical Indications and Therapeutic Uses

• Anxiety Disorders: BZDs for short-term relief of GAD, panic disorder, social anxiety, and phobias. SSRIs or buspirone are used for long-term management.
• Insomnia: Z-drugs are first-line pharmacotherapy; BZDs (short-term), melatonin agonists, and orexin antagonists are also used.
• Seizure Disorders: Diazepam and lorazepam for acute seizures; phenobarbital and clonazepam for chronic management.
• Acute Agitation: IV/IM lorazepam, haloperidol, or olanzapine in emergencies.
• Alcohol Withdrawal: Long-acting BZDs (chlordiazepoxide, diazepam) are preferred to prevent delirium tremens.
• Procedural Sedation: Midazolam is the most common agent due to amnesia and anxiolysis properties. Also propofol and ketamine.
• Anesthesia: Thiopental and propofol for induction; midazolam for premedication; dexmedetomidine for ICU sedation.
• Muscle Spasms: Diazepam is used for spinal and supraspinal muscle relaxation.

Adverse Effects and Safety Profile

• Neurological: Drowsiness, dizziness, cognitive impairment, and anterograde amnesia. Psychomotor impairment increases the risk of falls and accidents.
• Paradoxical Reactions: Agitation or aggression; more common in pediatric and geriatric populations.
• Respiratory: dose-dependent depression. Risk of apnea in patients with COPD or sleep apnea.
• Psychological: Physical and psychological dependence, and tolerance. Rebound anxiety and insomnia occur upon withdrawal.
• Z-Drug Specifics: Complex sleep behaviors like sleep-eating or sleep-walking.
• Other: Sexual dysfunction with chronic BZD use; metallic taste with eszopiclone.

Dependence, Tolerance, and Withdrawal Syndromes

• Tolerance: Occurs through $GABA_{A}$ receptor downregulation (decreased receptor count or affinity).
• Dependence Timeline: Physical dependence can develop within $2-4$ weeks of regular use. High-dose, long-acting BZDs present the highest risk.
• BZD Withdrawal Timeline:
  • $0-24\,h$ (Short-acting): Anxiety, insomnia, sweating, tremor.
  • $24-72\,h$ (Onset): Risk of seizures, delirium, and psychosis in severe cases.
  • $1-2$ weeks: Peak withdrawal; irritability, muscle cramps, perceptual disturbances.
  • $2-8$ weeks: Protracted syndrome; cognitive fog, emotional lability.
• Management: Gradual dose tapering (e.g., $10\%$ reduction per week), switching to long-acting BZDs, CBT, and carbamazepine as an adjunct.

Significant Drug Interactions

Contraindications and Precautions

Absolute Contraindications

• Known hypersensitivity/allergy to the drug class.
• Severe respiratory failure or depression.
• Obstructive sleep apnea (without CPAP).
• Acute narrow-angle glaucoma (specific to BZDs).
• Severe hepatic failure (risk of active metabolite accumulation).
• Myasthenia gravis (muscle relaxation worsens weakness).
• First trimester of pregnancy (potential risk of cleft palate).

Use with Caution

• Elderly: High risk for falls, hip fractures, and confusion.
• Children: Higher incidence of paradoxical reactions.
• History of Substance Abuse: High risk for misuse.
• COPD/Asthma: Requires monitoring of respiratory function.
• Driving: significant performance impairment should be expected.

Comparative Profile: BZDs vs. Barbiturates vs. Z-Drugs

Sedative Use in Special Populations

• Elderly Patients: Increased sensitivity and slower metabolism. Lorazepam is preferred. Beers Criteria recommends avoiding routine BZD use in this population.
• Pregnancy: BZDs are Category D. Risks include cleft palate and "floppy infant syndrome" (neonatal withdrawal). Use only if essential.
• Paediatrics: Phenobarbital is standard for neonatal seizures; midazolam for procedural sedation. Paradoxical disinhibition is a concern.
• Hepatic Impairment: Avoid drugs with active metabolites (Diazepam). Use the LOT rule (Lorazepam, Oxazepam, Temazepam).
• Renal Impairment: Monitor for accumulation of water-soluble metabolites.
• Substance Use Disorder: High risk of cross-dependence. Non-addictive alternatives like hydroxyzine or buspirone are preferred for anxiety.

Overdose Presentation and Clinical Management

• Presentation: Confusion, ataxia, slurred speech, profound sedation leading to coma, hypotension, and miosis. Respiratory depression is the primary cause of death.
• Management (ABCDE):
  • Airway/Breathing: Supplemental Oxygen or intubation/mechanical ventilation.
  • Circulation: IV fluids and vasopressors for hypotension.
  • Antidote: Flumazenil ($0.2\,mg$ IV for BZD overdose).
  • Exposure: Activated charcoal if ingested within $1-2\,h$.
• Flumazenil Cautions: Extremely short-acting ($t\frac{1}{2} \approx 1\,h$), so resedation can occur. It can precipitate status epilepticus if BZDs were used for seizure control, and it triggers acute withdrawal in dependent patients.

BZDs vs. SSRIs and Buspirone in Anxiety Management

Rational Prescribing Guidelines and Monitoring

• WHO/NICE Recommendations: Use the lowest effective dose for the shortest possible duration. BZDs for insomnia should not exceed $2-4$ weeks.
• Principles: Obtain informed consent concerning dependence and cognitive risks. Prioritize non-pharmacological approaches like Cognitive Behavioral Therapy for Insomnia (CBT-I).
• Monitoring: Assess response weekly at the start. Monitor for abuse patterns and behavioral changes. Conduct regular reassessments at $1$ month, $3$ months, and annually.

Sedatives in Specific Psychiatric Contexts

• Acute Psychotic Agitation: "Rapid tranquillisation" using IM lorazepam combined with IM haloperidol, or IM olanzapine alone. Do not combine IM BZDs and IM olanzapine due to respiratory risk.
• Alcohol Withdrawal: CIWA-Ar guided treatment with diazepam or chlordiazepoxide. Administer IV thiamine before glucose to prevent Wernicke encephalopathy.
• PTSD/Trauma: BZDs are generally not recommended as they mask symptoms and impair fear extinction. Prazosin is used for nightmares.
• OCD: BZDs may reduce acute anxiety during ERP therapy initiation but can impair the extinction learning process.
• Palliative Care: Midazolam infusions are used for refractory agitation or terminal sedation. Dexmedetomidine is preferred in the ICU to preserve respiratory drive.

New and Emerging Sedative Pharmacotherapies

• Dexmedetomidine (Igalmi): Sublingual form approved in $2022$ for acute agitation in schizophrenia/bipolar disorder. Provides sedation without respiratory depression.
• Neurosteroids:
  • Brexanolone (Zulresso): IV infusion for postpartum depression ($2019$ approval).
  • Zuranolone (Zurzuvae): Oral neurosteroid for MDD and PPD ($2023$ approval).
• Dual Orexin Receptor Antagonists (DORAs): Daridorexant ($2022$) was the first to demonstrate improvements in daytime function.
• Seltorexant: A selective $OX_{2}R$ antagonist currently in clinical trials.
• GABA-kines: Research stage drugs targeting extrasynaptic $GABA_{A}$ ($\delta$-subunit).
• Cannabis-based Medicines: THC/CBD derivatives being researched for PTSD-related insomnia, though evidence is currently limited.

Questions & Discussion

• Presenters: Alina Sajid ($011$), Aman Arshad ($012$), Nimra Naeem ($014$).
• Faculty Advisor: Dr. Iram Naz.